News | Published:

Pessimistic response to FDA leadership change

Subjects

  • An Erratum to this article was published on 01 February 2006

In September the commissioner of the FDA resigned, leaving a leadership vacuum and a lack of certainty that is likely to force biotech companies to stick to pharmaceutical alliances rather than going it alone in seeking drug approval.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Related links

Related links

Related links in Nature Research

https://doi.org/10.1038/Nat.Biotechnol.23,407-4072005

Web links

FDA

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Further reading